Covered Companies: Senti Bio
Most Recent Event
KOL Connect
Featuring: Senti Bio
April 21, 2025
Moderated discussion with Stephen Strickland, MD, MSCI, internationally respected leukemia researcher, Director of Leukemia Research for Sarah Cannon Research Institute and Kanya Rajangam, MD, PhD, President, Head of R&D and Chief Medical Officer of Senti Bio.
Senti Bio is a clinical-stage company that has built a synthetic biology platform that enables us to program next-generation cell and gene therapies with Gene Circuits.
NASDAQ: SNTI
About
Senti Bio is a clinical-stage company that has built a synthetic biology platform that enables us to program next-generation cell and gene therapies with Gene Circuits. These Gene Circuits, created from novel and proprietary combinations of DNA sequences, are designed to precisely kill cancer cells, spare healthy cells, increase specificity to target cells and control the expression of drugs even after administration. We are applying our Gene Circuit technologies to develop a pipeline of product candidates that use off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells.
Join Us
Sign up for email alerts to stay up-to-date on the latest Virtual Investor events
By submitting this form, you are consenting to receive marketing emails from: Virtual Investor. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact